Citations

Clear

1575 citation(s) found for "Im, Gene".

Human perforin gene variation is geographically distributed
Willenbring, Robin, Ikeda, Yasuhiro , Pease, Larry R. , Johnson, Aaron J. , Orozco, Robin C. , Willenbring, Robin C , Johnson, Aaron J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | December 7, 2017 | Volume: 6 | Issue: 1 | Pages: 44-55

10.1002/mgg3.344 | PMID 29216683 Get It

AbstractBackgroundDeleterious mutations in PRF1 result in lethal, childhood disease, familial hemophagocytic lymphohistiocytosis type 2 (FHL 2). However, not all mutations in PRF1 are deleterious and result in FHL 2. Currently, these nondeleterious mutations are being investigated in the onset of numerous disorders, such as lymphomas and diabetes. Yet, there is still an overwhelmingly large amount of PRF1 mutations that are not associated with disease.MethodsWe conducted a post hoc analysis of the PRF1 mutations in the coding region using the recently published Exome Aggregation Consortium genomes, Leiden Open Variation Database, NCBI SNP database, and primary literature to better understand PRF1 variation in the human population.ResultsThis study catalogs 460 PRF1 mutations in the coding region, and demonstrates PRF1 is more variant then previously predicted. We identify key PRF1 mutations with high allelic frequency and are only found in certain populations. Additionally, we define PRF1 SNVs are geographically distributed.ConclusionsThis study concludes with a novel hypothesis that nondeleterious mutation in PRF1, which decreases perforin expression and/or activity, may be an example of selective advantage in the context of environmental stressors prevalent near the equator. Our studies illustrate how perforin deficiency can be protective from injuries resulting in blood–brain barrier (BBB) disruption.
Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands’ Susceptibility Gene Mutation Status
Antwi, Samuel O. , Fagan, Sarah , Chaffee, Kari G. , Hu, Chunling , Lilyquist, Jenna , Oberg, Ann L. , Petersen, Gloria M. , Rabe, Kari G. , Polley, Eric C. , Hart, Steven N. , Shimelis, Hermela , Gnanaolivu, Rohan D., McWilliams, Robert R. , Antwi, Samuel O , Hu, Chunling , Bamlet, William R. , Gnanaolivu, Rohan , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 27, 2017 | Volume: 111 | Issue: 3 | Pages: 264-271

10.1093/jnci/djx272 | PMID 29982661 Get It

Gene Delivery to Joints by Intra-Articular Injection
Evans, Christopher H. , Ghivizzani, Steven C. , Robbins, Paul D.

Mayo Clinic

Human Gene Therapy | November 21, 2017 | Volume: 29 | Issue: 1 | Pages: 2-14

10.1089/hum.2017.181 | PMID 29160173 Get It

Most forms of arthritis are incurable, difficult to treat, and a major cause of disability in Western countries. Better local treatment of arthritis is impaired by the pharmacokinetics of the joint that make it very difficult to deliver drugs to joints at sustained, therapeutic concentrations. This is especially true of biologic drugs, such as proteins and RNA, many of which show great promise in preclinical studies. Gene transfer provides a strategy for overcoming this limitation. The basic concept is to deliver cDNAs encoding therapeutic products by direct intra-articular injection, leading to sustained, endogenous synthesis of the gene products within the joint. Proof of concept has been achieved for both in vivo and ex vivo gene delivery using a variety of vectors, genes, and cells in several different animal models. There have been a small number of clinical trials for rheumatoid arthritis (RA) and osteoarthritis (OA) using retrovirus vectors for ex vivo gene delivery and adeno-associated virus (AAV) for in vivo delivery. AAV is of particular interest because, unlike other viral vectors, it is able to penetrate deep within articular cartilage and transduce chondrocytes in situ. This property is of particular importance in OA, where changes in chondrocyte metabolism are thought to be fundamental to the pathophysiology of the disease. Authorities in Korea have recently approved the world's first arthritis gene therapy. This targets OA by the injection of allogeneic chondrocytes that have been transduced with a retrovirus carrying transforming growth factor-β 1 cDNA. Phase III studies are scheduled to start in the United States soon. Meanwhile, two additional Phase I trials are listed on Clinicaltrials.gov , both using AAV. One targets RA by transferring interferon-β, and the other targets OA by transferring interleukin-1 receptor antagonist. The field is thus gaining momentum and promises to improve the treatment of these common and debilitating diseases.
Pulmonary Neuroendocrine Cell Hyperplasia Associated with Surfactant Protein C Gene Mutation
Jiramethee, Norlalak , Erasmus, D , Nogee, Lawrence M. , Khoór, András , Erasmus, David, Nogee, Lawrence

Mayo Clinic

Case Reports in Pulmonology | November 9, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-6

10.1155/2017/9541419 | PMID 29250453 Get It

Familial interstitial lung disease (ILD) is defined as presence of ILD in 2 or more family members. Surfactant protein C (SFTPC) gene mutations are rare, but well-known cause of familial ILD. We reported a 20-year-old male, who was referred for lung transplantation. He was symptomatic at age 3 and underwent surgical lung biopsy at age 6, which revealed a nonspecific interstitial pneumonia (NSIP) pattern. Genetic workup revealed a novel SFTPC mutation in the first intron with a C to A transversion. At age 21, he underwent bilateral lung transplantation. Explanted lung histology suggested NSIP. In addition there was pulmonary neuroendocrine cell (PNEC) hyperplasia and carcinoid tumorlets. His mother had undergone lung transplantation several years earlier, and her explanted lung showed similar pathology. SFTPC mutations are inherited in an autosomal dominant pattern. Various types of ILD have been associated with SFTPC mutation including NSIP, usual interstitial pneumonia (UIP), and desquamative interstitial pneumonia (DIP). PNEC hyperplasia has been described to occur in association with lung inflammation but has not been previously described with familial ILD associated with SFTPC mutation.
Alveolar air and oxidative metabolic demand during exercise in healthy adults: the role of single-nucleotide polymorphisms of the β 2 AR gene
Iterson, Erik H. Van , Snyder, Eric M., Johnson, Bruce D., Van Iterson, Erik H

Mayo Clinic

Physiological Reports | October 23, 2017 | Volume: 5 | Issue: 20 | Pages: e13476

10.14814/phy2.13476 | PMID 29061864 Get It

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Lamichhane, Purushottam , Karyampudi, Lavakumar, Shreeder, Barath , Krempski, James , Bahr, Deborah, Daum, Joshua , Kalli, Kimberly R., Goode, Ellen L. , Block, Matthew S. , Cannon, Martin J. , Knutson, Keith L. , Krempski, James W , Knutson, Keith L.

Mayo Clinic

Cancer Research | October 9, 2017 | Volume: 77 | Issue: 23 | Pages: 6667-6678

10.1158/0008-5472.can-17-0740 | PMID 28993412 Get It

Abstract Ligation of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective adaptive antitumor immunity. Blockade of PD-1 in humans has resulted in impressive, durable regression responses in select tumor types. However, durable responses have been elusive in ovarian cancer patients. PD-1 was recently shown to be expressed on and thereby impair the functions of tumor-infiltrating murine and human myeloid dendritic cells (TIDC) in ovarian cancer. In the present work, we characterize the regulation of PD-1 expression and the effects of PD-1 blockade on TIDC. Treatment of TIDC and bone marrow–derived dendritic cells (DC) with IL10 led to increased PD-1 expression. Both groups of DCs also responded to PD-1 blockade by increasing production of IL10. Similarly, treatment of ovarian tumor–bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels in both serum and ascites. While PD-1 blockade or IL10 neutralization as monotherapies were inefficient, combination of these two led to improved survival and delayed tumor growth; this was accompanied by augmented antitumor T- and B-cell responses and decreased infiltration of immunosuppressive MDSC. Taken together, our findings implicate compensatory release of IL10 as one of the adaptive resistance mechanisms that undermine the efficacy of anti–PD-1 (or anti–PD-L1) monotherapies and prompt further studies aimed at identifying such resistance mechanisms. Cancer Res; 77(23); 6667–78. ©2017 AACR.
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus–Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination
Voigt, Emily A. , Haralambieva, Iana H. , Larrabee, Beth L, Kennedy, Richard B. , Ovsyannikova, Inna G. , Schaid, Daniel J. , Larrabee, Beth R. , Kennedy, Richard , Poland, Gregory A.

Mayo Clinic

The Journal of Infectious Diseases | October 3, 2017 | Volume: 217 | Issue: 4 | Pages: 560-566

10.1093/infdis/jix538 | PMID 29253144 Get It

Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Brimijoin, Stephen

Mayo Clinic

Proceedings of the National Academy of Sciences | October 2, 2017 | Volume: 114 | Issue: 41 | Pages: 10960-10965

10.1073/pnas.1706517114 | PMID 28973869 Get It

Significance Obesity is a major public health problem affecting physical and emotional well-being. Although lifestyle-based programs can help with weight loss, avoiding weight regain is nearly impossible because of persistent hormonal adaptations. Here, in mouse models, we explored a more effective strategy using viral gene transfer of butyrylcholinesterase (BChE) to control the appetite-mediating hormone acyl-ghrelin. We found that a single injection of BChE vector led to a lifetime high enzyme expression and lower circulating acyl-ghrelin. This same treatment suppressed postdieting hyperphagia, corrected metabolic lesions, and lowered weight regain. This outcome confirms the impact of the BChE-ghrelin axis on body weight and indicates that BChE gene transfer could be a successful strategy for long-term control of obesity and the “metabolic syndrome.”
An Efficient Test for Gene-Environment Interaction in Generalized Linear Mixed Models with Family Data
Mazo-Lopera, Mauricio Alejandro , Coombes, Brandon J. , Mazo Lopera, Mauricio A , de Andrade, Mariza, Andrade, Mariza de , Coombes, Brandon J

Mayo Clinic

International Journal of Environmental Research and Public Health | September 27, 2017 | Volume: 14 | Issue: 10 | Pages: 1134

10.3390/ijerph14101134 | PMID 28953253 Get It

Gene-environment (GE) interaction has important implications in the etiology of complex diseases that are caused by a combination of genetic factors and environment variables. Several authors have developed GE analysis in the context of independent subjects or longitudinal data using a gene-set. In this paper, we propose to analyze GE interaction for discrete and continuous phenotypes in family studies by incorporating the relatedness among the relatives for each family into a generalized linear mixed model (GLMM) and by using a gene-based variance component test. In addition, we deal with collinearity problems arising from linkage disequilibrium among single nucleotide polymorphisms (SNPs) by considering their coefficients as random effects under the null model estimation. We show that the best linear unbiased predictor (BLUP) of such random effects in the GLMM is equivalent to the ridge regression estimator. This equivalence provides a simple method to estimate the ridge penalty parameter in comparison to other computationally-demanding estimation approaches based on cross-validation schemes. We evaluated the proposed test using simulation studies and applied it to real data from the Baependi Heart Study consisting of 76 families. Using our approach, we identified an interaction between BMI and the Peroxisome Proliferator Activated Receptor Gamma (PPARG) gene associated with diabetes.
Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience
Botero, Juliana Perez , Coon, Lea M., Majerus, Julie A. , Chen, Dong , Pruthi, Rajiv K. , Perez Botero, Juliana , Chen, Dong

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 14, 2017 | Volume: 44 | Issue: 03 | Pages: 287-292

10.1055/s-0037-1605567 | PMID 28905352 Get It

AbstractIn hemophilia B (HB), factor IX gene (F9) genotyping is used for molecular confirmation of affected individuals, for carrier testing, to facilitate the identification of those at risk for anaphylaxis/inhibitors (associated with large deletions), and to assist in assigning disease severity. Owing to test costs, optimal test utilization involves pre/post-test counseling and appropriate patient and test selection (e.g., mutation screening [F9MS] vs. known mutation [F9KM] testing). This article aims to review the trends and outcomes of F9-genotyping orders and describe the spectrum of variants identified in a sample of individuals in our reference laboratory. We performed a retrospective review of consecutive orders submitted to the Special Coagulation DNA Diagnostic Laboratory, Mayo Clinic, between 2012 and 2015. A total of 133 orders (38%) were identified for men: 118 (88%) were F9MS and 15 (12%) were F9KM. Thirteen orders (10%) were cancelled. A total of 209 orders were identified for women: 178 (85%) were F9MS and 31 (15%) were F9KM. Thirty-seven orders (18%) were cancelled and 30% of the tests performed yielded negative results. A total of 164 samples (47%) were received without clinical information. Seventeen previously unreported variants were identified. F9 genotyping provides useful information for HB management; however, 18% of our orders were cancelled and almost half were received without relevant clinical information, thus reaffirming the need for ongoing scrutiny of submitted orders. Optimal patient and test selection is important as is the accurate interpretation of variants identified. Most of the pathogenic variants identified were point mutations, with very few large deletions, consistent with the literature.